Biosimilars Council Applauds FDA’s Efforts To Hear From Industry About Biosimilar Development

Comments On Biosimilar Development Are Welcomed Until 23 October

The US FDA is all ears. Stakeholders in the biosimilar industry have a chance to give their two cents about what would work best for development guidance.

Concept of brainstorming ideas
• Source: Shutterstock

The US Food and Drug Administration wants to hear from biosimilar developers on what is better for the industry: product-specific or class-specific guidances? And the biosimilars industry has welcomed such a request.

The Biosimilars Council, a division of the Association for Accessible Medicines, told Generics Bulletin that it “appreciates the FDA taking...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Regulation

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.